RTP Mobile Logo
Real-Life Oncology: Case-Based Discussions on the Biopsychosocial Management of Patients with Non-Hodgkin Lymphoma - Proceedings from a Satellite Symposium Held in Conjunction with the 2011 Oncology Nursing Society Annual Congress
Released August 2011

A comprehensive online training resource and self-directed educational activity that includes discussions of individual patient cases highlighting the importance of biopsychosocial and other variables in clinical decision-making, a review of recent clinical research findings and an exploration of optimal therapeutic and supportive care strategies for patients with non-Hodgkin lymphoma.

CE Disclosures and Faculty Information


    This activity is intended for oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.


    • Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of non-Hodgkin lymphomas, including chemotherapy regimens, radioimmunotherapy, biologic agents, immunomodulatory drugs, proteasome inhibitors and stem cell transplant.
    • Develop a plan to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Describe the role of risk stratification, cytogenetic testing and serial assessment of serum biomarkers in tailoring systemic treatment decisions for patients with non-Hodgkin lymphomas.


    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CNE activity contains a video component. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Gary Deng, MD, PhD

    Associate Member/Attending Physician
    Integrative Medicine Service
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    No real or apparent conflicts of interest to disclose.

    Amy Goodrich, CRNP-AC
    Nurse Practitioner
    Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    No real or apparent conflicts of interest to disclose.

    Mitchell R Smith, MD, PhD
    Director, Lymphoma Service
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: Pfizer Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    Mollie Moran, MSN, CNP, AOCNP
    The James Cancer Hospital at
    The Ohio State University
    Columbus, Ohio

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Cephalon Inc, Genentech BioOncology and Millennium: The Takeda Oncology Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WiFi is recommended for best performance):
ONS Non-Hodgkin Lymphoma Satellite - 2011Proceedings from a Satellite Symposium Held in Conjunction with the 2011 Oncology Nursing Society (ONS) Annual Congress